B7H3 x NKG2D NKE

N/A

Report date: 2025/01/26 18:20:43

Base Information

Drug NameB7H3 x NKG2D NKE
Drug Alias NameFc enhanced B7H3 x NKG2D bispecific NK-cell engager (Xencor)anti-NKG2D/anti-B7H3 bispecific NK-cell engager (Xencor)anti-NKG2D/anti-B7H3/anti-CD16 immune-cell engager (Xencor)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionLow affinity immunoglobulin gamma Fc region receptor III agonistsNKG2-D type II integral membrane protein agonistsCD276 antigen modulators
TargetsNKG2-D type II integral membrane proteinCD276 antigenLow affinity immunoglobulin gamma Fc region receptor III
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesXencor Inc
China Registration ClassN/A

Develop Information

Active CompaniesXencor Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A